Claritev Adjusts FY25 Revenue Forecast to 2.8%-3.2%, Up from Flat to 2%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
- Capital Expenditure Adjustment: The company has lowered its fiscal year 2025 capital expenditures forecast to a range of $165 million to $175 million.
- Previous Estimate Comparison: This revised estimate is a decrease from the earlier forecast of $170 million to $180 million.
Analyst Views on CTEV
Wall Street analysts forecast CTEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTEV is 85.00 USD with a low forecast of 80.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 30.470
Low
80.00
Averages
85.00
High
90.00
Current: 30.470
Low
80.00
Averages
85.00
High
90.00
About CTEV
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
